Clinical Trials Logo

Burkitt Lymphoma (BL)) clinical trials

View clinical trials related to Burkitt Lymphoma (BL)).

Filter by:
  • None
  • Page 1

NCT ID: NCT05049473 Recruiting - Clinical trials for Burkitt Lymphoma (BL)

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Start date: January 2014
Phase: Phase 2
Study type: Interventional

Rituximab combined with a specific intensive chemotherapy is considered the standard treatment for newly diagnosed patients with mature B leukemia/lymphoma. However, the toxicity of this therapy is high. The purpose of this trial is to reduce the dose intensity of the chemotherapy blocks once the patient has achieved complete response. With this approach the investigators expect to maintain the efficacy and to reduce the toxicity of the chemotherapy, specially the rate of deaths in complete response.

NCT ID: NCT03869619 Recruiting - Clinical trials for Follicular Lymphoma (FL)

REal World Data in LYmphoma and Survival in Adults

REALYSA
Start date: November 14, 2018
Phase:
Study type: Observational [Patient Registry]

REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data. REALYSA is a platform perfectly set up to - Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)… - Document treatment effectiveness in real life and observance - Address socio-economical questions

NCT ID: NCT02983097 Terminated - Clinical trials for Diffuse Large B-cell Lymphoma (DLBCL)

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

R²-DHAP
Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to evaluate efficacy and safety of the combination of lenalidomide, an immunomodulatory drug (IMiD) with a standard immunochemotherapy treatment, called R-DHAP. R-DHAP consists of a monoclonal antibody called Rituximab and chemotherapy consisting of Dexamethasone, high dose Cytarabine, often called Ara-C, and platinum based chemotherapy, either cisplatinum, or, if treatment with cisplatinum is contraindicated, carboplatinum.